의료기기 소프트웨어(SaMD) : 시장 인사이트, 경쟁 구도 및 시장 예측 - 2034년

Software as a Medical Device (SaMD) Market Summary

Overview:

• The global software as a medical device market was valued at USD 2.10 billion in 2025 and is projected to reach USD 8.90 billion by 2034.
• The market is expected to expand at a CAGR of 17.4% during the forecast period 2026-2034, supported by the integration of artificial intelligence and machine learning into clinical software, the growth of digital therapeutics and remote care, the maturation of regulatory pathways for software and adaptive algorithms, and the demand for diagnostic and decision support that improves care.
• By type, the diagnostic and screening software segment dominated the software as a medical device market with a 42% share in 2025.
• By application, the radiology and medical imaging segment dominated the software as a medical device market with a 34% share in 2025.
• By deployment, the cloud-based segment dominated the software as a medical device market with a 62% share in 2025.
• By end-user, the hospitals and clinics segment dominated the software as a medical device market with a 54% share in 2025.
• North America accounted for the largest share of the software as a medical device market at 45% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Software as a medical device is software intended to be used for one or more medical purposes that performs those purposes without being part of a hardware medical device. The scope encompasses diagnostic and screening software, including artificial intelligence tools that analyze medical images and data, clinical decision support software that informs and drives clinical management, digital therapeutics that treat and manage disease, and monitoring and treatment planning software, running on general-purpose computing platforms and increasingly powered by artificial intelligence and machine learning. Leading products include the LumineticsCore autonomous diagnostic software for diabetic retinopathy, the Viz.ai and Aidoc clinical artificial intelligence triage and detection tools, and digital therapeutics such as those developed by WellDoc and others, and the market is defined by the International Medical Device Regulators Forum framework and regulated by the Food and Drug Administration, the European Union Medical Device Regulation, and aligned national frameworks. The contemporary market is shaped by the integration of artificial intelligence, the growth of digital therapeutics, and the maturation of regulatory pathways for software and adaptive algorithms.

Software as a Medical Device (SaMD) Market Key Growth Drivers

• Integration of artificial intelligence and machine learning into clinical software, with the Food and Drug Administration having authorized a large and growing number of artificial intelligence-enabled devices.
• Growth of digital therapeutics and software-based treatment for chronic, behavioral, and neurological conditions.
• Maturation of regulatory pathways for software and adaptive algorithms, including the predetermined change control plan for artificial intelligence-enabled software.
• Demand for diagnostic and clinical decision support that improves the accuracy, speed, and access of care.
• Growth of remote monitoring, telehealth, and connected care that software as a medical device supports.
• Rising burden of chronic disease and the demand for scalable software-based diagnosis, monitoring, and treatment.
• Adoption of cloud and general-purpose computing platforms that deliver software as a medical device at scale.

Key Companies in Software as a Medical Device (SaMD) Market

The leading participants in the software as a medical device market include the following:

• Koninklijke Philips N.V.
• Siemens Healthineers AG
• GE HealthCare Technologies Inc.
• Medtronic plc
• Aidoc Medical Ltd.
• Viz.ai, Inc.
• Digital Diagnostics Inc.
• HeartFlow, Inc.
• Cognoa, Inc.
• Huma Therapeutics Limited

Factors Contributing to the Growth of the Software as a Medical Device (SaMD) Market

Market Drivers

Integration of Artificial Intelligence and Machine Learning into Clinical Software

The foundational driver of the software as a medical device market is the integration of artificial intelligence and machine learning into clinical software, which has transformed diagnosis, monitoring, and decision support. Artificial intelligence and machine learning enable software to analyze large volumes of medical data, including images, physiological signals, genetic data, and electronic health records, to detect patterns and conditions difficult for humans to detect, and the integration of these technologies into software as a medical device has revolutionized diagnostics, monitoring, treatment support, and decision-making. The Food and Drug Administration has authorized a large and growing number of artificial intelligence-enabled medical devices, with the authorized list expanding to exceed a thousand entries and double from earlier years, and the majority are software that analyzes images and data in radiology, cardiology, and other specialties. Artificial intelligence software detects and triages disease, prioritizes urgent findings, supports diagnosis, and recommends evidence-based actions, and its ability to learn from real-world use and improve performance makes it a rapidly expanding area of development. The transformation of clinical software by artificial intelligence, the authorization of artificial intelligence-enabled software, and the value of artificial intelligence in diagnosis and decision support drive the growth of the market. As artificial intelligence and machine learning are integrated into clinical software and as authorized artificial intelligence software expands, the market grows. The integration of artificial intelligence and machine learning into clinical software anchors the growth of the software as a medical device market across the forecast period.

Growth of Digital Therapeutics and Software-Based Treatment

The growth of digital therapeutics and software-based treatment is a defining driver that expands software as a medical device from diagnosis into treatment. Digital therapeutics are software that treats, manages, or prevents disease through evidence-based therapeutic interventions, and they have been developed and cleared for chronic, behavioral, and neurological conditions, including diabetes, substance use, and other disorders. Digital therapeutics integrate behavioral, cognitive, and lifestyle interventions with software delivery, treating conditions through applications that patients use on general-purpose devices, and cleared digital therapeutics deliver cognitive behavioral therapy, disease management, and neurological therapy. The growth of digital therapeutics is driven by the value of scalable, accessible, software-based treatment, the evidence of clinical efficacy, and the demand for treatment of chronic and behavioral conditions, and it expands software as a medical device from diagnosis and monitoring into treatment. Digital therapeutics complement or substitute for pharmacotherapy, extend treatment to underserved populations, and support the management of chronic and behavioral conditions, and their development and clearance expand the market. As digital therapeutics grow and as software-based treatment is developed and cleared, the software as a medical device market expands into treatment. The growth of digital therapeutics and software-based treatment sustains demand for software as a medical device across the forecast period.

Market Restraints

The software as a medical device market faces several interrelated restraints that temper its growth. The foremost is the complexity and burden of regulation, since software as a medical device is regulated as a medical device requiring clearance or approval, clinical evidence, and quality and lifecycle management, and the cost, time, and complexity of regulatory submission and compliance, particularly for higher-risk software and across multiple jurisdictions, are substantial and can be a barrier, especially for smaller developers.

The challenge of regulating adaptive and learning algorithms persists, since artificial intelligence software that learns and changes challenges the traditional model of device authorization, and while the predetermined change control plan addresses this, its adoption is still developing, and fully autonomous continuous learning is not yet permitted without predetermined protocols and validation. Reimbursement is a significant challenge, since the reimbursement of software as a medical device and digital therapeutics is limited, evolving, and inconsistent, and the absence of established reimbursement pathways constrains the business model and adoption.

Clinical validation and evidence generation are demanding and costly, since software must demonstrate safety, effectiveness, and clinical benefit, and the generation of clinical evidence requires studies, time, and investment. Clinical adoption and integration face barriers of clinician acceptance, workflow integration, integration with electronic health records and clinical systems, and the demonstration of value, and the adoption of software into clinical practice can be slow. Data privacy, security, and quality obligations, and the risk of bias and the requirement for performance across populations, add compliance burden and risk. Liability and the assignment of responsibility for software-driven decisions raise legal and clinical questions. Together, these factors moderate the pace and scope of adoption and require developers to demonstrate regulatory compliance, clinical evidence, reimbursement, and value to sustain growth.

Software as a Medical Device (SaMD) Market Segment Analysis

The global software as a medical device market is segmented by type (diagnostic and screening software, clinical decision support software, digital therapeutics, and monitoring and treatment planning software), by application (radiology and medical imaging, cardiology, neurology, ophthalmology, and others), by deployement (cloud-based and on premise and embedded), and by end-users (hospitals, patients and consumers, diagnostic and imagaing centers,, and others) by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Type

Dominant Subsegment: Diagnostic and Screening Software.

The diagnostic and screening software category is expected to dominate the market. The diagnostic and screening software segment accounted for a 42% share of the software as a medical device market in 2025. Diagnostic and screening software, including the artificial intelligence tools that analyze medical images and data to detect, characterize, and triage disease, is the leading type because it is the largest and most mature category of software as a medical device, comprising the majority of authorized artificial intelligence-enabled software and addressing the high-value applications of diagnosis and screening. The dominance of the segment reflects the maturity and volume of diagnostic artificial intelligence, the concentration of authorized software in diagnosis and screening, and the clinical and commercial value of accurate and scalable diagnosis. Diagnostic and screening software analyzes images and data in radiology, cardiology, ophthalmology, pathology, and other specialties to detect and triage disease, and the majority of authorized artificial intelligence-enabled devices are diagnostic software. The maturity of diagnostic artificial intelligence, the volume of authorized diagnostic software, and the value of diagnosis and screening drive the segment. While clinical decision support, digital therapeutics, and monitoring software are important and growing types, the maturity, volume, and value of diagnostic and screening software sustain the leadership of the diagnostic and screening software segment across the forecast period.

By Application

Dominant Subsegment: Radiology and Medical Imaging.

The radiology and medical imaging category is expected to dominate the market. The radiology and medical imaging segment accounted for a 34% share of the software as a medical device market in 2025. Radiology and medical imaging is the leading application because it is the most developed and highest-volume area of software as a medical device, with the majority of artificial intelligence-enabled software analyzing medical images to detect, characterize, and triage disease. The dominance of the segment reflects the concentration of artificial intelligence software in imaging, the volume and value of imaging analysis, and the maturity of imaging artificial intelligence. Software analyzes radiological images, including computed tomography, magnetic resonance, and other modalities, to detect and triage conditions such as stroke, fractures, nodules, and other findings, prioritizing urgent cases and supporting radiologists; the majority of authorized artificial intelligence software is in radiology and imaging. The volume of imaging, the value of imaging analysis and triage, and the maturity of imaging artificial intelligence drive the segment. While cardiology, ophthalmology, neurology, oncology, and other applications are significant and growing, the concentration, volume, and maturity of radiology and medical imaging sustain the leadership of the radiology and medical imaging segment across the forecast period.

Software as a Medical Device (SaMD) Market Region Analysis

Dominant Region: North America

North America accounted for a 45% share of the global software as a medical device market in 2025, representing the highest regional market share globally. The leadership of the region reflects the advanced regulatory framework for software and artificial intelligence, the concentration of clinical artificial intelligence and digital health companies, the advanced adoption of clinical software, and the strength of research and investment. The United States is the largest national market, supported by the Food and Drug Administration framework and pathways for software and artificial intelligence-enabled devices, the authorization of a large and growing number of artificial intelligence-enabled devices, the concentration of clinical artificial intelligence, imaging, and digital therapeutics companies, and the advanced adoption of clinical software. The Food and Drug Administration has developed tailored policies, pathways, and guidance for software as a medical device, including the predetermined change control plan for artificial intelligence-enabled software, and the advanced healthcare and technology ecosystem supports the development and adoption of software. The leading clinical artificial intelligence, imaging, and digital therapeutics companies are headquartered or operate extensively in the region, and the adoption of diagnostic, triage, and decision support software is advanced. The advanced regulatory framework, the concentration of companies, the adoption of software, and the strength of investment reinforce the leadership of the region. The combination of regulatory maturity, company concentration, adoption, and investment sustains the position of North America as the largest regional market across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region combines large and growing populations, the expansion of healthcare and digital infrastructure, the growth of artificial intelligence and digital health, and the increasing adoption of clinical software, which drives the fast growth of the market. China, Japan, India, and South Korea are the principal national markets, supported by the growth of healthcare investment and digital infrastructure, the development of artificial intelligence and digital health industries, the rising burden of chronic disease, and the increasing adoption of diagnostic and clinical software. The growth of healthcare and digital infrastructure, the development of artificial intelligence and digital health, and the adoption of clinical software enlarge the demand for software as a medical device. As healthcare and digital infrastructure expand, as artificial intelligence and digital health develop, and as clinical software is adopted, the region increases its adoption from a growing base, and the scale of the population and the growth of digital health create substantial long-term demand. The combination of population scale, infrastructure expansion, artificial intelligence and digital health growth, and software adoption positions Asia-Pacific as the fastest-growing regional market, and it attracts investment and commercial focus from the leading global and regional companies.

Regional Commentary

North America

North America leads the market, supported by the advanced regulatory framework for software and artificial intelligence, the concentration of clinical artificial intelligence and digital health companies, the advanced adoption of clinical software, and the strength of research and investment. The United States dominates the region through the Food and Drug Administration framework for software and artificial intelligence, the authorization of artificial intelligence-enabled devices, and the concentration of companies. The advanced ecosystem and adoption sustain demand.

Europe

Europe is a substantial market shaped by the regulation of software under the European Union Medical Device Regulation, which classifies standalone software with a medical purpose as a medical device, the adoption of clinical software, and the presence of medical technology and digital health companies. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, supported by the adoption of clinical artificial intelligence and digital health, the regulation of software as a medical device, and the emerging artificial intelligence regulation. Demand is sustained by the adoption of diagnostic and clinical software and the growth of digital health.

Asia-Pacific

Asia-Pacific is the fastest-growing region, driven by large and growing populations, the expansion of healthcare and digital infrastructure, the growth of artificial intelligence and digital health, and the increasing adoption of clinical software across China, Japan, India, and South Korea. Infrastructure expansion, artificial intelligence and digital health growth, and software adoption sustain rapid growth, and the region attracts commercial focus from the leading global and regional companies.

Rest of World

The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as healthcare and digital infrastructure expand and as clinical software is adopted. Growth is supported by the growth of digital health, the adoption of diagnostic and clinical software, and the expansion of access, though adoption and regulatory maturity vary by market. Companies pursue these markets through cloud-delivered software suited to expanding digital health.

Software as a Medical Device (SaMD) Market Competitive Landscape

The global software as a medical device market is classified as Fragmented. A large and diverse group of participants competes across the categories of software as a medical device, including medical technology and imaging companies, clinical artificial intelligence specialists, digital therapeutics companies, and health technology companies, and no single participant holds a dominant share of the diverse and rapidly evolving market. Competition centers on the clinical performance and validation of the software, the regulatory clearance and pathway, the integration with clinical workflow and systems, the breadth of clinical applications, the intelligence of the artificial intelligence, reimbursement, and clinical adoption; clearances, launches, and investment intensify the contest. The competitive landscape is evaluated across the following dimensions:

• Market concentration: Fragmented, with medical technology and imaging companies, clinical artificial intelligence specialists, digital therapeutics companies, and health technology companies, and no single participant holding a dominant share of the diverse and rapidly evolving market.
• Leading players: Philips, Siemens Healthineers, GE HealthCare, and Medtronic lead among the medical technology and imaging companies; Aidoc, Viz.ai, Digital Diagnostics, and HeartFlow lead in clinical artificial intelligence, and Cognoa, Huma, and digital therapeutics companies contest the treatment and platform categories.
• Geographic reach: The medical technology and imaging companies operate globally, and clinical artificial intelligence and digital therapeutics specialists expand from their home markets, with concentration in North America and Europe.
• Product portfolio strength: Competitive advantage rests on the clinical performance and validation of the software, the breadth of clinical applications, the integration with imaging and clinical systems, and the intelligence and adaptability of the artificial intelligence.
• Pipeline strength: Development is concentrated in artificial intelligence diagnostic and triage software, digital therapeutics, clinical decision support, and the expansion of clinical applications and indications.
• Strategic partnerships: Collaboration spans integration with imaging and electronic health record systems, partnerships with health systems and pharmaceutical companies, and alliances that extend clinical validation, distribution, and reimbursement.
• M&A activity: Consolidation has shaped the field, with medical technology and imaging companies acquiring clinical artificial intelligence and software companies and platforms consolidating clinical artificial intelligence, alongside continued investment and consolidation.
• Innovation focus: Innovation is shifting toward advanced artificial intelligence diagnostic and triage software, digital therapeutics, adaptive and learning algorithms with change control, and the integration and platforming of clinical software.
• Regulatory standing: Clearance and authorization by the Food and Drug Administration, conformity under the European Union Medical Device Regulation, alignment with the International Medical Device Regulators Forum framework, and the adoption of the predetermined change control plan for adaptive software are decisive competitive credentials and a principal axis of competition among the leaders.

Software as a Medical Device (SaMD) Market Recent Developmental Activities

In 2021, the Food and Drug Administration published its artificial intelligence and machine learning software as a medical device action plan, setting out a framework for the oversight of artificial intelligence and machine learning-based software. Strategic significance: the action plan advanced the tailored regulation of artificial intelligence software and shaped the development of subsequent guidance.

In June 2023, Huma Therapeutics Limited received Food and Drug Administration Class II clearance for a disease-agnostic software as a medical device platform, enabling the configuration of regulated software across conditions. Strategic significance: the clearance advanced the platform model of software as a medical device and enabled the rapid configuration of regulated software.

Software as a Medical Device (SaMD) Market Segmentation

Software as a Medical Device (SaMD) Market Assessment by Type

• Diagnostic and Screening Software
• Clinical Decision Support Software
• Digital Therapeutics
• Monitoring and Treatment Planning Software

Software as a Medical Device (SaMD) Market Assessment by Application

• Radiology and Medical Imaging
• Cardiology
• Neurology
• Ophthalmology
• Others

Software as a Medical Device (SaMD) Market Assessment by Deployment

• Cloud-Based
• On-Premise and Embedded

Software as a Medical Device (SaMD) Market Assessment by End-User

• Hospitals and Clinics
• Patients and Consumers
• Diagnostic and Imaging Centers
• Others

Software as a Medical Device (SaMD) Market Assessment by Geography

• North America
• United States Software as a Medical Device Market Size in USD million (2023-2034)
• Canada Software as a Medical Device Market Size in USD million (2023-2034)
• Mexico Software as a Medical Device Market Size in USD million (2023-2034)
• Europe
• Germany Software as a Medical Device Market Size in USD million (2023-2034)
• United Kingdom Software as a Medical Device Market Size in USD million (2023-2034)
• France Software as a Medical Device Market Size in USD million (2023-2034)
• Italy Software as a Medical Device Market Size in USD million (2023-2034)
• Spain Software as a Medical Device Market Size in USD million (2023-2034)
• Rest of Europe Software as a Medical Device Market Size in USD million (2023-2034)
• Asia-Pacific
• China Software as a Medical Device Market Size in USD million (2023-2034)
• Japan Software as a Medical Device Market Size in USD million (2023-2034)
• India Software as a Medical Device Market Size in USD million (2023-2034)
• Australia Software as a Medical Device Market Size in USD million (2023-2034)
• South Korea Software as a Medical Device Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Software as a Medical Device Market Size in USD million (2023-2034)
• Rest of the World
• Middle East Software as a Medical Device Market Size in USD million (2023-2034)
• Africa Software as a Medical Device Market Size in USD million (2023-2034)
• South America Software as a Medical Device Market Size in USD million (2023-2034)

Key Takeaways from the Software as a Medical Device (SaMD) Market Report Study

• Market size analysis for the current software as a medical device market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key software, artificial intelligence, and regulatory developments, clearances, partnerships, and investments that happened over the last 3 years.
• Key companies dominating the global software as a medical device market.
• Various opportunities available for competitors in the software as a medical device market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current software as a medical device market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for software as a medical device market growth in the future?

Target audience who can benefit from this software as a medical device market report study

• Software as a medical device, clinical artificial intelligence, and digital therapeutics providers
• Research organizations and consulting companies
• Software as a medical device-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Hospitals, health systems, and medical technology companies dealing in clinical software
• Various end-users who want to know more about the software as a medical device market and the latest technological developments in the software as a medical device market.

Frequently Asked Questions:

Q1. At what rate is the software as a medical device market expected to grow?

The global software as a medical device market is projected to grow at a compound annual growth rate of 17.4% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the software as a medical device market?

The global software as a medical device market was valued at USD 2.10 billion in 2025 and is projected to reach USD 8.90 billion by 2034.

Q3. Which region dominates the software as a medical device market?

North America dominated the software as a medical device market with a 45% share in 2025, driven by the advanced regulatory framework for software and artificial intelligence, the concentration of clinical artificial intelligence and digital health companies, the advanced adoption of clinical software, and the strength of research and investment, with the Food and Drug Administration having authorized a large and growing number of artificial intelligence-enabled devices. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by the expansion of healthcare and digital infrastructure and the growth of artificial intelligence and digital health across China, Japan, India, and South Korea.

Q4. What are the key factors driving growth in the software as a medical device market?

The principal drivers are the integration of artificial intelligence and machine learning into clinical software; the growth of digital therapeutics and software-based treatment; the maturation of regulatory pathways for software and adaptive algorithms, including the predetermined change control plan; the demand for diagnostic and clinical decision support; the growth of remote monitoring, telehealth, and connected care; and the rising burden of chronic disease and the demand for scalable software.

Q5. Who are the major players in the software as a medical device market?

The market is fragmented and led by Koninklijke Philips N.V., Siemens Healthineers AG, GE HealthCare Technologies Inc., Medtronic plc, and Aidoc Medical Ltd., alongside Viz.ai, Inc., Digital Diagnostics Inc., HeartFlow, Inc., Cognoa, Inc., and Huma Therapeutics Limited. Additional participants, including Cleerly, Inc., Paige.AI, Inc., and RapidAI, compete across clinical artificial intelligence, imaging, and digital therapeutics software.

Table of Contents

1. Introduction

• 1.1. Scope of the Report
• 1.2. Market Segmentation
• 1.3. Market Overview at a Glance

2. Executive Summary of Software as a Medical Device (SaMD) Market

• 2.1. Key Highlights and Market Snapshot

3. Key Factors Impacting the Software as a Medical Device (SaMD) Market

• 3.1. Market Drivers
  • 3.1.1. Integration of Artificial Intelligence and Machine Learning into Clinical Software
  • 3.1.2. Growth of Digital Therapeutics and Software-Based Treatment
  • 3.1.3. Maturation of Regulatory Pathways for Software and Adaptive Algorithms
  • 3.1.4. Diagnostic Support, Connected Care, and Scalable Software
• 3.2. Market Restraints
  • 3.2.1. Regulatory Complexity and Adaptive Algorithm Challenges
  • 3.2.2. Reimbursement and Clinical Validation Constraints
  • 3.2.3. Clinical Adoption, Integration, and Liability
• 3.3. Market Opportunities
  • 3.3.1. Artificial Intelligence, Digital Therapeutics, and Adaptive Software
  • 3.3.2. Emerging Markets and Connected Care

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

• 5.1. The United States
• 5.2. Europe
• 5.3. Japan
• 5.4. China

6. Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Software as a Medical Device (SaMD) Market Assessment

• 7.1. By Type
  • 7.1.1. Diagnostic and Screening Software
  • 7.1.2. Clinical Decision Support Software
  • 7.1.3. Digital Therapeutics
  • 7.1.4. Monitoring and Treatment Planning Software
• 7.2. By Application
  • 7.2.1. Radiology and Medical Imaging
  • 7.2.2. Cardiology
  • 7.2.3. Neurology
  • 7.2.4. Ophthalmology
  • 7.2.5. Others
• 7.3. By Deployment
  • 7.3.1. Cloud-Based
  • 7.3.2. On-Premise and Embedded
• 7.4. By End-User
  • 7.4.1. Hospitals and Clinics
  • 7.4.2. Patients and Consumers
  • 7.4.3. Diagnostic and Imaging Centers
  • 7.4.4. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.1.2. Canada Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.1.3. Mexico Software as a Medical Device Market Size in USD million (2023-2034)
  • 7.5.2. Europe
    • 7.5.2.1. Germany Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.2.2. United Kingdom Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.2.3. France Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.2.4. Italy Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.2.5. Spain Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.2.6. Rest of Europe Software as a Medical Device Market Size in USD million (2023-2034)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.3.2. Japan Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.3.3. India Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.3.4. Australia Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.3.5. South Korea Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.3.6. Rest of Asia-Pacific Software as a Medical Device Market Size in USD million (2023-2034)
  • 7.5.4. Rest of the World
    • 7.5.4.1. Middle East Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.4.2. Africa Software as a Medical Device Market Size in USD million (2023-2034)
    • 7.5.4.3. South America Software as a Medical Device Market Size in USD million (2023-2034)

8. Software as a Medical Device (SaMD) Market Competitive Landscape

• 8.1. Competitive Analysis
• 8.2. Company Share Analysis (Premium Offering)

9. Software as a Medical Device (SaMD) Market Startup Funding and Investment Trends

10. Company and Product Profiles

• 10.1. Koninklijke Philips N.V.
  • 10.1.1. Company Overview
  • 10.1.2. Company Snapshot
  • 10.1.3. Financial Overview
  • 10.1.4. Product Portfolio
  • 10.1.5. Strategic Initiatives / Entropy
• 10.2. Siemens Healthineers AG
  • 10.2.1. Company Overview
  • 10.2.2. Company Snapshot
  • 10.2.3. Financial Overview
  • 10.2.4. Product Portfolio
  • 10.2.5. Strategic Initiatives / Entropy
• 10.3. GE HealthCare Technologies Inc.
  • 10.3.1. Company Overview
  • 10.3.2. Company Snapshot
  • 10.3.3. Financial Overview
  • 10.3.4. Product Portfolio
  • 10.3.5. Strategic Initiatives / Entropy
• 10.4. Medtronic plc
  • 10.4.1. Company Overview
  • 10.4.2. Company Snapshot
  • 10.4.3. Financial Overview
  • 10.4.4. Product Portfolio
  • 10.4.5. Strategic Initiatives / Entropy
• 10.5. Aidoc Medical Ltd.
  • 10.5.1. Company Overview
  • 10.5.2. Company Snapshot
  • 10.5.3. Financial Overview
  • 10.5.4. Product Portfolio
  • 10.5.5. Strategic Initiatives / Entropy
• 10.6. Viz.ai, Inc.
  • 10.6.1. Company Overview
  • 10.6.2. Company Snapshot
  • 10.6.3. Financial Overview
  • 10.6.4. Product Portfolio
  • 10.6.5. Strategic Initiatives / Entropy
• 10.7. Digital Diagnostics Inc.
  • 10.7.1. Company Overview
  • 10.7.2. Company Snapshot
  • 10.7.3. Financial Overview
  • 10.7.4. Product Portfolio
  • 10.7.5. Strategic Initiatives / Entropy
• 10.8. HeartFlow, Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Company Snapshot
  • 10.8.3. Financial Overview
  • 10.8.4. Product Portfolio
  • 10.8.5. Strategic Initiatives / Entropy
• 10.9. Cognoa, Inc.
  • 10.9.1. Company Overview
  • 10.9.2. Company Snapshot
  • 10.9.3. Financial Overview
  • 10.9.4. Product Portfolio
  • 10.9.5. Strategic Initiatives / Entropy
• 10.10. Huma Therapeutics Limited
  • 10.10.1. Company Overview
  • 10.10.2. Company Snapshot
  • 10.10.3. Financial Overview
  • 10.10.4. Product Portfolio
  • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us